GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Sartorius AG (CHIX:SRT3d) » Definitions » EV-to-EBIT

Sartorius AG (CHIX:SRT3D) EV-to-EBIT : 45.41 (As of Dec. 15, 2024)


View and export this data going back to 2012. Start your Free Trial

What is Sartorius AG EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Sartorius AG's Enterprise Value is €18,077 Mil. Sartorius AG's EBIT for the trailing twelve months (TTM) ended in Sep. 2024 was €398 Mil. Therefore, Sartorius AG's EV-to-EBIT for today is 45.41.

The historical rank and industry rank for Sartorius AG's EV-to-EBIT or its related term are showing as below:

CHIX:SRT3d' s EV-to-EBIT Range Over the Past 10 Years
Min: 11.27   Med: 32.6   Max: 79.18
Current: 45.41

During the past 13 years, the highest EV-to-EBIT of Sartorius AG was 79.18. The lowest was 11.27. And the median was 32.60.

CHIX:SRT3d's EV-to-EBIT is ranked worse than
80.49% of 446 companies
in the Medical Devices & Instruments industry
Industry Median: 20.71 vs CHIX:SRT3d: 45.41

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Sartorius AG's Enterprise Value for the quarter that ended in Sep. 2024 was €21,098 Mil. Sartorius AG's EBIT for the trailing twelve months (TTM) ended in Sep. 2024 was €398 Mil. Sartorius AG's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2024 was 1.89%.


Sartorius AG EV-to-EBIT Historical Data

The historical data trend for Sartorius AG's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sartorius AG EV-to-EBIT Chart

Sartorius AG Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 41.55 57.71 52.22 21.28 44.72

Sartorius AG Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 34.01 44.72 48.53 42.64 47.47

Competitive Comparison of Sartorius AG's EV-to-EBIT

For the Medical Instruments & Supplies subindustry, Sartorius AG's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sartorius AG's EV-to-EBIT Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Sartorius AG's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Sartorius AG's EV-to-EBIT falls into.



Sartorius AG EV-to-EBIT Calculation

Sartorius AG's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=18076.605/398.1
=45.41

Sartorius AG's current Enterprise Value is €18,077 Mil.
Sartorius AG's EBIT for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €398 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sartorius AG  (CHIX:SRT3d) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Sartorius AG's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Sep. 2024 ) =EBIT / Enterprise Value (Q: Sep. 2024 )
=398.1/21098.04487
=1.89 %

Sartorius AG's Enterprise Value for the quarter that ended in Sep. 2024 was €21,098 Mil.
Sartorius AG's EBIT for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €398 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sartorius AG EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Sartorius AG's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Sartorius AG Business Description

Address
Otto-Brenner-Strasse 20, Gottingen, NI, DEU, 37079
Sartorius AG is a leading provider of bioprocessing solutions. Its Bioprocess division sells equipment and consumables for upstream and downstream manufacturing of biologic drugs, and has a focus on single-use technology, or SUT. Its Lab Products and Services division offers a wide range of products for lab use, including scales, pipettes, and filtration equipment. As of 2022, the Bioprocess and LPS divisions contributed 80% and 20% of revenue, respectively. Bioprocess is housed in its subsidiary Sartorius Stedim Biotech, of which Sartorius AG has a 74% ownership and 85% voting control. The business is geographically diverse, with revenue across Europe, the Middle East, and Africa (37% of 2022 sales), the Americas (37%), and Asia-Pacific (26%). We estimate China revenue to be around 10%.

Sartorius AG Headlines

No Headlines